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Introduction
Since licensure in 2006, two rotavirus vaccines have been increasingly used worldwide to 
prevent rotavirus diarrhea morbidity and mortality in children less than 5 years of age. 
RotaTeq (Merck and Co) is a three-dose pentavalent bovine-human reassortant rotavirus 
vaccine and Rotarix (GSK Biologics) is a two-dose monovalent human rotavirus vaccine [1, 
2]. Two other three-dose vaccines, ROTAVAC (Bharat Biotech) and ROTASIIL (Serum 
Institute of India), were licensed recently and are under review for World Health 
Organization (WHO) prequalification [3, 4].
Rotavirus vaccines are licensed for use as part of the infant immunization schedule 
concomitantly with diphtheria-tetanus-pertussis vaccine (DTP). Randomized control trials 
(RCT) for Rotarix and RotaTeq assessed vaccine efficacy beyond the first year of life; in low 
income countries, waning immunity after 1 year of age was observed in clinical trials [5, 6] 
while protection was found to persist in the RCTs in high income countries [7]. Some post-
licensure, “real world” effectiveness evaluations in several low and middle-income settings 
also indicate there may be waning protection after the first year of life, though they were not 
sufficiently powered to detect differential vaccine performance by age group [8–18]. Rotarix 
VE after 12 months of age was found to be a median of 31% lower in middle income 
countries, compared to 5% higher in high income countries in a recent systematic literature 
review [19]. These observations raise concern that waning immunity may leave vaccinated 
children vulnerable to rotavirus diarrhea morbidity and mortality in the second year of life 
and beyond. In the absence of vaccine, approximately 30% of rotavirus deaths occur during 
the second year of life, though this varies substantially from region to region [20]. A booster 
dose of rotavirus vaccine later in infancy has been proposed as an approach to address 
waning rotavirus vaccine immunity [21].
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Measles-containing vaccines (MCV) are generally recommended by national immunization 
programs for administration at 9 or 12 months of age. Delivering a booster dose of rotavirus 
vaccine at the same healthcare visit as MCV could be a logistically feasible way to integrate 
a booster dose of rotavirus vaccine into the Expanded Programme on Immunization (EPI) 
and extend protection into the second year of life. A RTC in Bangladesh recently 
demonstrated non-interference of a rotavirus vaccine dose delivered concomitantly with the 
injected, live measles-rubella vaccine, a necessary first step in determining feasibility of 
such a strategy [21]. As a secondary objective, the RTC assessed immunogenicity of the 
booster rotavirus vaccine dose; all children in the study received 2 infant doses of rotavirus 
vaccine. Among children in Bangladesh who were sero-negative at 9 months, 44% 
seroconverted after receiving a third dose of rotavirus vaccine with MCV, compared with 6% 
of placebo recipients. While seroconversion is not directly correlated with clinical outcomes 
[22], these results are encouraging.
Before any policy recommendation for a 9- or 12-month dose of RV can be considered, the 
potential benefits of booster dose will need to be weighed against the additional cost and 
vaccine supply requirements. Additionally, a clinical efficacy or large-scale immunogenicity 
trials will need to be conducted, which will be resource intensive. As a critical first step in 
deciding whether to pursue this strategy, we aimed to evaluate the potential impact of a 
booster dose of rotavirus vaccine on rotavirus mortality.
Methods
Using UNICEF 2014 <5 child mortality rates, we divided countries into three strata. Low 
mortality countries were defined as those with rates in the lowest quartile (1.9 to 7 deaths per 
1,000 live births), medium mortality countries as those in the second lowest quartile (8 to 17 
deaths per 1,000 live births), and high mortality countries as those in the highest two 
quartiles (18 to 157 deaths per 1,000 live births) [23]. Countries categorized in the medium 
and high mortality strata are included in this exercise; countries with low child mortality 
were not, as waning protection of rotavirus vaccine has not been observed in these settings.
Model construction
We calculated national reductions in rotavirus deaths as follows:
where i refers to country and j to the week of life. In this formula, VE refers to vaccine 
effectiveness and Coverage refers to full series rotavirus vaccine coverage.
We followed the PRISMA guidelines in a systematic literature review of full-series rotavirus 
vaccine VE estimates from medium- and high-mortality countries published between 1 
January 2006 and 2 December 2016 using the PubMed, MEDLINE, Embase, and Global 
Health databases. The methods are described in detail elsewhere [19]. Briefly, we included 
post-licensure, observational evaluations that reported Rotarix VE estimates for children <12 
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months of age and children ≥12 months of age in low and middle income countries against 
hospitalization for rotavirus disease. Additionally, we included two pre-licensure evaluations 
that address waning in low and middle income countries [5, 6, 8–18]. We calculated 
summary VE estimates with a random effects model (Table 1); this portion of analysis was 
performed using R v3.2.4. We considered three functional forms for VE waning. In the 
stepwise model, we assumed full VE is achieved at 6 weeks of age and remains constant 
until waning at 9 months of age; in this model, VE is constant from 9 to 24 month of age 
(Figures 1a and 1b). This model reflects the results of the meta-analysis, which summarize 
VE estimates from children in these broad age categories. We used the same <9 month and 
≥9 month point estimates and 95%CIs to generate logarithmic and linear waning patterns by 
assigning the VE point estimates to 6 months of age and 18 months of age (Figures 1c and 
1d). VE estimates by week of age generated by the three waning forms were included as 
model inputs.
Full series vaccination coverage by country was obtained from the WHO/Unicef annual 
Joint Reporting Form (JRF), which provides a “best estimate” of national vaccine-specific 
coverage for children <12 months of age using administrative data, surveys, and other 
national estimates [24]. The JRF reports full series rotavirus vaccine coverage for countries 
that have introduced rotavirus vaccine in their national immunization programs. However in 
this exercise, we assumed full series rotavirus vaccine coverage to be equal to DTP coverage 
for all countries from 6 weeks of age, regardless of rotavirus vaccine introduction status or 
recommended schedule. As rotavirus vaccine is usually recommended for co-administration 
with DTP, coverage is expected to be similar for both vaccines. In countries that have 
introduced rotavirus vaccine, some countries have experienced an initial lag in coverage 
compared to DTP. We assumed coverage with a booster dose of rotavirus vaccine would be 
equal to first-dose measles or full-series DTP coverage, whichever was least [25].
The estimated national rotavirus deaths and distribution of deaths by week of age used in 
this exercise were previously published and were most recently updated in 2013 [20, 26, 27].
Booster Scenarios
We calculated the baseline number of rotavirus deaths for each functional waning form. For 
countries that had not introduced rotavirus vaccine before 2013 we calculated the baseline 
number of deaths due to rotavirus, assuming that the primary series was introduced, by 
subtracting the number of deaths prevented under each of the three waning scenarios from 
the estimated number of rotavirus deaths in 2013. Among countries that introduced rotavirus 
vaccine before 2013, we used the number of rotavirus deaths in 2013 as baseline under all 
three waning scenarios.
Given that the true effect of a booster does is unknown, we simulated three scenarios with 
each waning model: (a) reduced VE waning in the second year of life by 50%, (b) 
reestablished second year of life VE to levels from the first year of life, and (c) boosted VE 
by 50% of the difference between VE in the first and second years of life. In all boosting 
scenarios, the slope and functional form of waning is assumed to be the same before and 
after the booster rotavirus vaccine dose. Regardless of vaccine introduction status, the 
number of deaths prevented under the nine boosting scenarios were calculated the same way 
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for all countries. Summary results are presented globally and by WHO region. Booster doses 
were assumed to be administered concomitantly with MCV at either 9 or 12 months, based 
on the current recommended age of administration by country.
Simulations
To quantify uncertainty in averted death estimates, we performed a sensitivity analysis by 
generating 1,000 simulations of each model. We independently sampled <12 month and ≥12 
month VE from a normal distribution from the confidence intervals generated by the meta-
analysis; the number of rotavirus deaths in 2013 from a normal distribution from the 
published confidence intervals; and coverage from +/− 5% of the JRF estimates, assuming a 
uniform distribution. Vaccination coverage was not allowed to exceed 100%. We then 
calculated the median number of deaths prevented and the point estimate at the 2.5 and 97.5 
percentiles as the confidence interval from the 1,000 samples. Model calculations and 
simulations were performed using SAS v9.4.
Results
Eleven studies, 9 post-licensure and 2 pre-licensure, from 9 countries met the meta-analysis 
inclusion criteria (Figure 2) These articles were included in the random effects model to 
estimate a pooled VE (Table 1). VE for children <12 months of age was estimated to be 66% 
(95%CI: 57, 73); VE for children ≥12 months of age was estimated to be 45% (95%CI: 29, 
57).
We assumed all countries had introduced a primary rotavirus vaccine series in calculating 
baseline deaths due to rotavirus disease. Across all WHO regions, we calculated an 
estimated 122,400 (95%CI: 119000, 126200), 113,300 (95%CI: 109900, 116700), and 
114,200 (95%CI: 110700, 117700), deaths under the stepwise, logarithmic, and linear 
baseline waning models, respectively (Table 2).
Globally under the stepwise model, there were 9,800 (95%CI: 9400, 10200), 19,600 
(95%CI: 18800, 20400), and 29400 (95%CI: 28200, 30700) additional rotavirus deaths 
averted when a booster rotavirus dose reduced VE waning, reestablished VE, and boosted 
VE, respectively (Table 2). This represents 8%, 16%, and 24% fewer rotavirus deaths 
compared with the estimated stepwise model baseline deaths. Under the logarithmic model, 
there were 3,100 (95%CI: 3000, 3200), 6,200 (95%CI: 5900, 6400), and 9,200 (95%CI: 
8900, 9600) additional rotavirus deaths averted when a booster rotavirus dose reduced VE 
waning, reestablished VE, and boosted VE, respectively. This represents 3%, 5%, and 8% 
fewer rotavirus deaths compared with the estimated logarithmic model baseline deaths. 
Under the linear model, there were 1,200 (95%CI: 1900, 2100), 4,000 (95%CI: 3800, 4200), 
and 6,100 (95%CI: 5900, 6400) additional rotavirus deaths averted when a booster rotavirus 
dose reduced VE waning, reestablished VE, and boosted VE, respectively. This represents 
2%, 3%, and 5% fewer deaths compared with the estimated linear model waning baseline 
deaths. For all scenarios the greatest number of additional deaths averted was in the AFRO 
region (due to the relative high mortality in that region), while the greatest proportion of 
additional deaths averted was in the SEARO region (due to the older age distribution of 
rotavirus deaths in that region).
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We reevaluated some of our initial assumptions under the stepwise waning model. If all 
countries administered a booster dose of rotavirus vaccine at 9 months rather than 12 
months, 107 (95%CI: 103, 111), 214 (95%CI: 206, 223), and 667 (95%CI: 308, 334) 
additional estimated rotavirus deaths would be averted under the reduced VE waning, 
reestablished VE, and boosted VE scenarios, respectively. Our assumption that primary 
series rotavirus vaccination coverage equaled DTP full series coverage in countries that have 
already introduced rotavirus vaccine accounted for 373 (95%CI: 333, 419), 746 (95%CI: 
666, 837), and 1119 (95%CI: 999, 1265) rotavirus deaths averted under the reduced VE 
waning, reestablished VE, and boosted VE scenarios, respectively.
Discussion
We found from 4,000 (95%CI: 3800, 4200) to 19,600 (95%CI: 18800, 20400) additional 
rotavirus deaths could be averted in medium and high child mortality countries if a booster 
dose of rotavirus vaccine reestablished VE to the levels in the first year of life during the 
second year of life. This represents a 3–16% reduction in estimated deaths due to rotavirus 
disease as compared to estimated baseline deaths. The absolute number of rotavirus deaths 
averted varied significantly by region, baseline burden of disease, and age distribution of 
rotavirus deaths. For example, the African Region had the highest number of rotavirus 
deaths in 2013 and, in absolute numbers, saw the biggest decline in the three baseline 
models; all nine boosting scenarios showed substantial impacts, ranging from nearly 900 
deaths to over 13,100 deaths averted. Though the Southeast Asia Region had about half the 
number of baseline deaths as the African Region, the absolute number of deaths averted was 
only slightly lower in the Southeast Asia compared to the African Region. This is because in 
Asia more deaths are in older children than in African Region countries, and thus a booster 
dose has greater benefits.
While there is a lot of uncertainty in the form and degree of waning for rotavirus vaccine 
after the first year of life, the three models we proposed as a structural uncertainty analysis 
were consistent in estimating the baseline number of deaths. Each region the nine models 
and boosting scenarios produced a wide range of deaths averted. For example, the stepwise 
model ranged from 51% in the European Region to 81% in the Western Pacific Region than 
the linear models under the boosted VE scenario. These discrepancies highlight the need for 
better understanding of the mechanism and patterns of waning rotavirus vaccine induced 
immunity. While more refined inputs would improve our estimates, much of the uncertainty 
in our estimates is between the three waning forms. Inferring the temporal patterns of 
waning may not be possible in standard vaccine trials and relatively large age groups, one 
year in this case, do not provide the necessary granularity to determine if waning follows a 
stepwise, logarithmic or linear pattern. Moreover, over time, the placebo arm in a trial 
becomes more similar to the vaccine group by natural infection, making it difficult to 
disentangle true loss of immunity and measurement bias.
This exercise had several additional limitations. Most importantly, there remains uncertainty 
about the relationship between seroconversion and clinical endpoints, limiting our ability to 
quantify the impact of a booster dose from current immunogenicity data. Trial data with a 
clinical endpoint will narrow the range of plausible assumptions. Our model does not 
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account for herd immunity or catch-up vaccination for the primary rotavirus vaccine series. 
The meta-analysis provided VE estimates for a range of ages and we assigned these 
estimates to specific time points to generate the linear and logarithmic waning models. 
Future research may provide more age-specific VE estimates to improve our assumptions. 
Finally, this analysis focused on regional and global impact of introducing a booster dose, 
however we may be overlooking important differences at the country- or subnational-levels.
These results show the potential for an important impact on rotavirus diarrhea mortality by 
adding a booster dose of rotavirus vaccine administered at 9 or 12 months of age. However, 
the benefits of booster will have to be weighed against considerations of additional cost, 
vaccine supply needed, safety, and programmatic considerations. Nonetheless, these results 
inform consideration of booster doses of rotavirus vaccine.
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Figure 1a. Stepwise rotavirus immunity waning model with 9 month recommended age of 
measles-containing vaccine administration
Figure 1b. Stepwise rotavirus immunity waning model with 12 month recommended age of 
measles-containing vaccine administration
Figure 1c. Linear rotavirus immunity waning model with 9 and 12 month recommended age 
of measles-containing vaccine administration
Figure 1d. Logarithmic rotavirus immunity waning model with 9 and 12 month 
recommended age of measles-containing vaccine administration
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Article review and selection process.
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